This article is linked to Chapman et al and Nicolaides et al papers. To view thses articles, visit https://doi.org/10.1111/apt.15771 and https://doi.org/10.1111/apt.16107
Nicolaides S, Vasudevan A, van Langenberg D. Letter: rationalising aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther. 2020;52:1618-1618.
Chapman TP, Frias Gomes C, Louis E, et al. Review article: withdrawal of 5-aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther. 2020;52:73-84.
Singh S, Kim J, Zhu W, et al. No benefit of continuing vs stopping 5-aminosalicylates in patients with ulcerative colitis escalated to anti-metabolite therapy. Aliment Pharmacol Ther. 2020;52:481-491.
Brenner EJ, Ungaro RC, Gearry RB, et al. Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an International Registry. Gastroenterology. 2020;159:481-491.e3.
Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369:m1966.
Grundy EJ, Suddek T, Filippidis FT, et al. Smoking, SARS-CoV-2 and COVID-19: a review of reviews considering implications for public health policy and practice. Tob Induc Dis. 2020;18:58.
